BioCentury | Apr 24, 2006
Company News

Hapto, Ortec deal

...acquisition of Hapto for 30.9 million shares (see BioCentury, Dec. 19, 2005). The deal values Hapto...
...based on ORTC's close of $0.32 on April 17, the day the deal was completed. Hapto Biotech Inc....
BioCentury | Dec 19, 2005
Company News

Hapto, Ortec deal

...ORTN), New York, N.Y. Business: Gene/Cell therapy ORTN signed a letter of intent to acquire Hapto...
...on ORTN's close of $0.18 on Dec. 14, the day before the deal was announced. Hapto...
...to purchase ORTN stock at $0.35. The deal is expected to close within 45 days. Hapto...
BioCentury | May 30, 2005
Clinical News

Hapto, Ortec preclinical data

...ulcers. OrCel is FDA approved to treat epidermolysis bullosa and donor sites in burn patients. Hapto Biotech Inc....
BioCentury | Oct 18, 2004
Company News

Hapto, Ortec deal

...wound healing and tissue regeneration. The compounds were identified under a 2002 research deal using Hapto's...
...bilayered cellular matrix technology. The companies plan to out-license resulting products for co-development and commercialization. Hapto Biotech Inc....
BioCentury | Oct 11, 2004
Company News

Hapto, Ortec biomaterial JV

...wound healing and tissue regeneration. The compounds were identified under a 2002 research deal using Hapto's...
BioCentury | Oct 7, 2002
Company News

Hapto Biotech Ltd., Ortec deal

...matrix technology with Hapto's Haptide synthetic peptide technology, which enhances cell attachment and facilitates growth. Hapto...
Items per page:
1 - 6 of 6
BioCentury | Apr 24, 2006
Company News

Hapto, Ortec deal

...acquisition of Hapto for 30.9 million shares (see BioCentury, Dec. 19, 2005). The deal values Hapto...
...based on ORTC's close of $0.32 on April 17, the day the deal was completed. Hapto Biotech Inc....
BioCentury | Dec 19, 2005
Company News

Hapto, Ortec deal

...ORTN), New York, N.Y. Business: Gene/Cell therapy ORTN signed a letter of intent to acquire Hapto...
...on ORTN's close of $0.18 on Dec. 14, the day before the deal was announced. Hapto...
...to purchase ORTN stock at $0.35. The deal is expected to close within 45 days. Hapto...
BioCentury | May 30, 2005
Clinical News

Hapto, Ortec preclinical data

...ulcers. OrCel is FDA approved to treat epidermolysis bullosa and donor sites in burn patients. Hapto Biotech Inc....
BioCentury | Oct 18, 2004
Company News

Hapto, Ortec deal

...wound healing and tissue regeneration. The compounds were identified under a 2002 research deal using Hapto's...
...bilayered cellular matrix technology. The companies plan to out-license resulting products for co-development and commercialization. Hapto Biotech Inc....
BioCentury | Oct 11, 2004
Company News

Hapto, Ortec biomaterial JV

...wound healing and tissue regeneration. The compounds were identified under a 2002 research deal using Hapto's...
BioCentury | Oct 7, 2002
Company News

Hapto Biotech Ltd., Ortec deal

...matrix technology with Hapto's Haptide synthetic peptide technology, which enhances cell attachment and facilitates growth. Hapto...
Items per page:
1 - 6 of 6